{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T03:38:54Z","timestamp":1774669134786,"version":"3.50.1"},"reference-count":32,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.<\/jats:p>","DOI":"10.2340\/actadv.v105.43523","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:58:21Z","timestamp":1759474701000},"page":"adv43523","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations"],"prefix":"10.2340","volume":"105","author":[{"given":"Niccolo","family":"Gori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvise","family":"Sernicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Elena Ippoliti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Paganini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia","family":"Tolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Panasiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Boeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabatino","family":"Pallotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"128750","doi-asserted-by":"crossref","unstructured":"Gori N, Chiricozzi A, Marsili F, Ferrucci SM, Amerio P, Battarra V, et al. National information campaign revealed disease characteristic and burden in adult patients suffering from atopic dermatitis. J Clin Med 2022; 11: 5204.","DOI":"10.3390\/jcm11175204"},{"key":"128751","doi-asserted-by":"crossref","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers 2018; 4: 1.","DOI":"10.1038\/s41572-018-0001-z"},{"key":"128752","doi-asserted-by":"crossref","unstructured":"Talamonti M, Galluzzo M, Silvaggio D, Lombardo P, Tartaglia C, Bianchi L. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med 2021; 10: 1298.","DOI":"10.3390\/jcm10061298"},{"key":"128753","doi-asserted-by":"crossref","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. SOLO 1 and SOLO 2 investigators: two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335\u20132348.","DOI":"10.1056\/NEJMoa1610020"},{"key":"128754","doi-asserted-by":"crossref","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo- controlled, phase 3 trial. Lancet 2017; 389: 2287\u20132303.","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"128755","doi-asserted-by":"crossref","unstructured":"Deleuran M, Tha\u00e7i D, Beck LA, de Bruin-Weller M, Blauvelt A, Forman S, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol 2020; 82: 377\u2013388.","DOI":"10.1016\/j.jaad.2019.07.074"},{"key":"128756","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Wollenberg A, Eichenfield LF, Zhang H, Sierka D, Khokhar FA, et al. No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab. Adv Ther 2023; 40: 367\u2013380.","DOI":"10.1007\/s12325-022-02322-y"},{"key":"128757","doi-asserted-by":"crossref","unstructured":"Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat 2022; 33: 1146\u20131149.","DOI":"10.1080\/09546634.2020.1773379"},{"key":"128758","doi-asserted-by":"crossref","unstructured":"Gori N, Sernicola A, Tolino E, Mariano M, Galluzzo M, Moretta G, et al. Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study. J Dermatolog Treat 2023; 34: 2230685.","DOI":"10.1080\/09546634.2023.2230685"},{"key":"128759","doi-asserted-by":"crossref","unstructured":"Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol 2023; 37: 1135\u20131148.","DOI":"10.1111\/jdv.18922"},{"key":"128760","doi-asserted-by":"crossref","unstructured":"Patruno C, Potestio L, Scalvenzi M, Battista T, Raia F, Picone V, et al. Dupilumab for the treatment of adult atopic dermatitis in special populations. J Dermatolog Treat 2022; 33: 3028\u20133033.","DOI":"10.1080\/09546634.2022.2102121"},{"key":"128761","doi-asserted-by":"crossref","unstructured":"Edmonds N, Zhao P, Flowers RH. The use of dupilumab in patients with HIV. Int J STD AIDS 2022; 33: 1165\u20131173.","DOI":"10.1177\/09564624221129406"},{"key":"128762","doi-asserted-by":"crossref","unstructured":"Alawadhi A, Karibayeva D, Gottlieb AB. Dupilumab in HIV-positive patients: a case series report of 4 patients. JAAD Case Rep 2020; 6: 1356\u20131359.","DOI":"10.1016\/j.jdcr.2020.09.023"},{"key":"128763","doi-asserted-by":"crossref","unstructured":"Avallone G, Trunfio M, Giura MT, Siliquini N, Viola R, Orofino G, et al. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review. Dermatol Online J 2021; 27.","DOI":"10.5070\/D327854709"},{"key":"128764","doi-asserted-by":"crossref","unstructured":"Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol 2023; 37: 1135\u20131148.","DOI":"10.1111\/jdv.18922"},{"key":"128765","doi-asserted-by":"crossref","unstructured":"Ly K, Smith MP, Thibodeaux Q, Beck K, Bhutani T, Liao W. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Rep 2019 2; 5: 624\u2013626.","DOI":"10.1016\/j.jdcr.2019.05.007"},{"key":"128766","doi-asserted-by":"crossref","unstructured":"Mota F. Atopic dermatitis patient with hepatitis C treated with dupilumab: a case report. Actas Dermosifiliogr 2024; 115: 420\u2013421.","DOI":"10.1016\/j.ad.2022.07.038"},{"key":"128767","doi-asserted-by":"crossref","unstructured":"Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential risks related to modulating interleukin-13 and interleukin-4 signalling: a systematic review. Drug Saf 2018; 41: 489\u2013509.","DOI":"10.1007\/s40264-017-0636-9"},{"key":"128768","doi-asserted-by":"crossref","unstructured":"Metko D, Alkofide M, Abu-Hilal M. A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities. JAAD Int 2024; 15: 5\u201311.","DOI":"10.1016\/j.jdin.2024.01.002"},{"key":"128769","doi-asserted-by":"crossref","unstructured":"Tanczosova M, Hugo J, Gkalpakiotis S. Treatment of severe atopic dermatitis with dupilumab in patients with advanced cancer. J Clin Med 2023; 12: 1191.","DOI":"10.3390\/jcm12031191"},{"key":"128770","doi-asserted-by":"crossref","unstructured":"Siliquini N, Giura MT, Viola R, Ribero S, Panzone M, Dapavo P, et al. Atopic dermatitis, dupilumab and cancers: a case series. J Eur Acad Dermatol Venereol 2021; 35: e651\u2013652.","DOI":"10.1111\/jdv.17264"},{"key":"128771","doi-asserted-by":"crossref","unstructured":"Talmon A, Elias S, Rubin L, Ribak Y, Ben Dori E, Shamriz O, et al. Dupilumab for cancer-associated refractory pruritus. J Allergy Clin Immunol Glob 2023; 2: 100128.","DOI":"10.1016\/j.jacig.2023.100128"},{"key":"128772","doi-asserted-by":"crossref","unstructured":"Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis: what does the evidence say? J Allergy Clin Immunol 2023; 151: 1155\u20131162.","DOI":"10.1016\/j.jaci.2022.12.002"},{"key":"128773","doi-asserted-by":"crossref","unstructured":"Jalles C, Lepelley M, Mouret S, Charles J, Leccia MT, Trabelsi S. Skin cancers under Janus kinase inhibitors: a World Health Organization drug safety database analysis. Therapie 2022; 77: 649\u2013656.","DOI":"10.1016\/j.therap.2022.04.005"},{"key":"128774","doi-asserted-by":"crossref","unstructured":"Hasan I, Parsons L, Duran S, Zinn Z. Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study. J Am Acad Dermatol 2024; 91: 255\u2013258.","DOI":"10.1016\/j.jaad.2024.03.039"},{"key":"128775","doi-asserted-by":"crossref","unstructured":"Stuver R, Dusza S, Epstein-Peterson ZD, Ghione P, Horwitz SM, Johnson W, et al. Cutaneous T-cell lymphoma and dupilumab use: a retrospective matched cohort study of clinical characteristics and treatment outcomes. J Eur Acad Dermatol Venereol 2025; 39: e114\u2013e117.","DOI":"10.1111\/jdv.20141"},{"key":"128776","doi-asserted-by":"crossref","unstructured":"Mazzetto R, Miceli P, Tartaglia J, Ciolfi C, Sernicola A, Alaibac M. Role of IL-4 and IL-13 in cutaneous T cell lymphoma. Life (Basel) 2024; 14: 245.","DOI":"10.3390\/life14020245"},{"key":"128777","doi-asserted-by":"crossref","unstructured":"Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 2021; 22: 581\u2013586.","DOI":"10.1007\/s40257-021-00597-5"},{"key":"128778","doi-asserted-by":"crossref","unstructured":"Foti C, Romita P, Ambrogio F, Manno C, Filotico R, Cassano N, et al. Treatment of severe atopic dermatitis with dupilumab in three patients with renal diseases. Life (Basel). 2022; 12: 2002.","DOI":"10.3390\/life12122002"},{"key":"128779","doi-asserted-by":"crossref","unstructured":"Laageide L, Verhave B, Samkoff L, Looney R, Beck L. Relapsing-remitting multiple sclerosis arising in a patient with atopic dermatitis on dupilumab. JAAD Case Rep 2021; 15: 33\u201335.","DOI":"10.1016\/j.jdcr.2021.07.003"},{"key":"128780","doi-asserted-by":"crossref","unstructured":"Gelato F, Mastorino L, Cavalla P, Quaglino P, Cavaliere G, Vercellino M, et al. Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: a case report. Dermatol Ther 2022; 35: e15740.","DOI":"10.1111\/dth.15740"},{"key":"128781","doi-asserted-by":"crossref","unstructured":"Esposito M, De Berardinis A, Totaro R, Fargnoli MC. Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis. JAAD Case Rep 2023; 31: 1\u20135.","DOI":"10.1016\/j.jdcr.2022.10.031"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43523\/51654","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/43523\/51654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:58:31Z","timestamp":1759474711000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/43523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2340\/actadv.v105.43523","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}